T-cell Acute Lymphoblastic Leukemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Key Highlights

• Major factor that is responsible for the growth of T-cell acute lymphoblastic leukaemia market is the rising prevalence of T-cell acute lymphoblastic leukaemia globally.
• T-cell Acute Lymphoblastic Leukemia Treatment estimated for 15% to 20% of all acute lymphoblastic leukemia by study of the American Society of Clinical Oncology (ASCO). The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that, in 2019, there were around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females.
• Additionally, growing research and development expenditure on cancer therapeutics, increasing healthcare expenditure and innovations in novel drug development are also propelling the growth of the T-cell acute lymphoblastic leukaemia market globally.
• However, stringent regulations for the approval of T-ALL drugs, high cost of the treatment and adverse effects associated with therapies are the factors that may hamper the growth of the market.

Key Market Trends

Chemotherapy dominate the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

• The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy drugs are the cell-killing therapeutics. These drugs kill the cancer cells and stop them from dividing.
• Chemotherapy is normally given as a combination of drugs and for T-ALL, will always include steroids. T-ALL cells is found in the cerebro spinal fluid (CSF) so chemotherapy for the T-ALL includes injections into CSF. This is called intrathecal chemotherapy. This is more common in T-ALL than in other forms of ALL.

North America Dominates the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

North America holds a significant market share in the global T-ALL Treatment market and is expected to withstand its position over the forecast period. The diagnosis and prevalence rates of T-ALL is growing rapidly in the region. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

Competitive Landscape

Currently, many private companies are focusing on the development and introduction of novel therapeutics. Additionally, extensive research and development activities are being initiated by most of the market players, government organizations and academic research institutes. Some of the key innovations in the market are: In 2017, Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration in specific gene, known as Capicua, has been inactivated and that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support